Table 2 Evaluation items before, during and after treatment
Eligibility | Inclusion in trial | Planning of RT (week − 2) | CCRT (week 0–8) | End of EBRT (week 5) | Follow-up 1 (month 3) | Follow-up 2 (month 6) |
|---|---|---|---|---|---|---|
Written informed consent | ✓ | |||||
Demographic information | ✓ | |||||
Medical History (incl. Histology) | ✓ | ✓ | ✓ | |||
Physical Examination | ✓ | ✓ | ✓ | ✓ | ||
Staging imaging | ✓ | ✓ | ✓ | ✓ | ||
Pathological results | ✓ | |||||
HPV testing | ✓ | ✓ | ||||
Blood samples (Blood routine, hepatic and renal function, SCC, etc.) | ✓ | ✓ | ✓ | ✓ | ✓ | |
Planning CT | ✓ | |||||
Image-guidance during RT | ✓ | |||||
Toxicity (NCI CTC AE V5.0) | ✓ | ✓ | ✓ | ✓ |